Collaborations to Support RSV Surveillance and Assess RSV-Associated Morbidity and Mortality: Laying the Groundwork for Vaccine Introduction in the United States and Updates from CDC

Wednesday, June 7, 2017: 1:00 PM
Snake, Boise Centre
Mila M. Prill , Centers for Disease Control and Prevention, Atlanta, GA
Brian Rha , Centers for Disease Control and Prevention, Atlanta, GA
Lindsay Kim , Centers for Disease Control and Prevention, Atlanta, GA
Susan Gerber , Centers for Disease Control and Prevention, Atlanta, GA

Key Objectives:

  1. Discuss CDC’s current activities to assess RSV burden and RSV-associated morbidity and mortality
  2. Discuss experiences with RSV surveillance from state, territorial, and local public health perspectives
  3. Identify and discuss epidemiologic evidence gaps prior to potential vaccine introduction in the United States
  4. Conduct strategic planning for future collaborations between CDC and CSTE related to RSV

Brief Summary:
 Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in children younger than 1 year of age in the United States and is being increasingly recognized as a significant cause of respiratory illness in older adults. With more than 50 vaccine products and other therapeutics in development, it is important to document disease burden through surveillance in all age groups and to assess RSV-associated morbidity and mortality prior to potential vaccine introduction. With support from local and state partners, CDC activities include: 1) the expansion of active, population-based surveillance through the New Vaccine Surveillance Network (NVSN) to determine the etiology and burden of acute viral respiratory diseases among children in inpatient and emergency department settings; 2) monitoring RSV seasonality in the US through the National Respiratory and Enteric Virus Surveillance System (NREVSS), a laboratory-based system; 3) investigating and validating RSV-coded deaths of children <5 year of age since 2014; 4) active, prospective surveillance among hospitalized adults through the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) and at a Veteran’s Affairs hospital; 5) population-based surveillance for laboratory-confirmed RSV among hospitalized adults through the Influenza Surveillance Network (FluSurv-NET) 6) surveys focused on laboratory practices related to RSV detection and assessing the knowledge, attitudes, and practices of clinicians with regard to diagnosing RSV; and 7) conducting pilot studies to assess viral etiology of respiratory infections among residents in adult long-term care and pediatric chronic care facilities. Discussion will mainly focus on laboratory and disease surveillance, documenting disease burden, and proposed next steps for more accurately assessing pediatric mortality.